F
Francesca De Franco
Researcher at University of Perugia
Publications - 23
Citations - 1088
Francesca De Franco is an academic researcher from University of Perugia. The author has contributed to research in topics: Bile acid & Chemistry. The author has an hindex of 12, co-authored 17 publications receiving 868 citations. Previous affiliations of Francesca De Franco include European Institute of Oncology & Intercept Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells
Andrea Viale,Francesca De Franco,Francesca De Franco,Annette Orleth,Annette Orleth,Valeria Cambiaghi,Virginia Giuliani,Daniela Bossi,Chiara Ronchini,Simona Ronzoni,Ivan Muradore,Silvia Monestiroli,Alberto Gobbi,Myriam Alcalay,Myriam Alcalay,Saverio Minucci,Saverio Minucci,Pier Giuseppe Pelicci,Pier Giuseppe Pelicci +18 more
TL;DR: It is demonstrated that expression of the cell-cycle inhibitor p21 is indispensable for maintaining self-renewal of leukaemia stem cells and suggested that inhibition of DNA repair mechanisms might function as potent strategy for the eradication of the slowly proliferating leukaemias.
Journal ArticleDOI
De novo NAD + synthesis enhances mitochondrial function and improves health
Elena Katsyuba,Adrienne Mottis,Marika Zietak,Marika Zietak,Francesca De Franco,Vera van der Velpen,Karim Gariani,Karim Gariani,Dongryeol Ryu,Dongryeol Ryu,Lucia Cialabrini,Olli Matilainen,Olli Matilainen,Paride Liscio,Nicola Giacchè,Nadine Stokar-Regenscheit,Nadine Stokar-Regenscheit,David Legouis,Sophie de Seigneux,Julijana Ivanisevic,Nadia Raffaelli,Kristina Schoonjans,Roberto Pellicciari,Johan Auwerx +23 more
TL;DR: Genetic or pharmacological inhibition of α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase increases NAD+ and improves mitochondrial function in nematodes and mice, and may have therapeutic potential in kidney and liver disease.
Journal ArticleDOI
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
Giovanni Rizzo,Daniela Passeri,Francesca De Franco,Gianmario Ciaccioli,Loredana Donadio,G. Rizzo,Stefano Orlandi,Bahman M. Sadeghpour,Xiaoxin X. Wang,Tao Jiang,Moshe Levi,Mark Pruzanski,Luciano Adorini +12 more
TL;DR: Preclinical results indicate that INT-767 is a safe and effective modulator of FXR and TGR5-dependent pathways, suggesting potential clinical applications in the treatment of liver and metabolic diseases.
Journal ArticleDOI
Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
Aldo Roda,Roberto Pellicciari,Antimo Gioiello,Flavia Neri,Cecilia Camborata,Daniela Passeri,Francesca De Franco,Silvia Spinozzi,Carolina Colliva,Luciano Adorini,Marco Montagnani,Rita Aldini +11 more
TL;DR: Minor structural modifications profoundly influence the metabolism and biodistribution in the target organs where semisynthetic bile acid analogs exert therapeutic effects by interacting with FXR and/or TGR5 receptors.
Journal ArticleDOI
Probing the Binding Site of Bile Acids in TGR5.
Antonio Macchiarulo,Antimo Gioiello,Charles Thomas,Thijs W.H. Pols,Roberto Nuti,Cristina Ferrari,Nicola Giacchè,Francesca De Franco,Mark Pruzanski,Johan Auwerx,Kristina Schoonjans,Roberto Pellicciari +11 more
TL;DR: An integrated computational, chemical, and biological approach is presented that has been instrumental to determine the binding mode of BAs to TGR5, and key residues have been identified that are involved in mediating the binding of B as to the receptor.